Cholestech

Privately held cholesterol and lipid disorders drug R&D firm, raises $11.6 mil. in third round of venture capital financing, bringing total raised to date to $24 mil. New funding will be used to bring L-D-X lipid monitoring system to market and to advance human clinicals on its first therapeutic, a "non-fibrate drug" for reducing low-density lipoprotein (LDL) while increasing HDL levels. The product, already approved in Europe, has been in Phase II trials since January 1989 ("The Pink Sheet" Feb. 27, 1989, T&G-10).